Orexo Q1 2024 Interim Report
Orexo Q1 2024 Interim Report |
[08-May-2024] |
UPPSALA, Sweden, May 8, 2024 /PRNewswire/ -- Starting 2024 with a positive EBITDA Q1 2024 highlights
Important events after the end of the period
CEO Comments in brief: Creating a stable financial platform I am pleased to report a significant improvement in our financial results with an EBITDA increasing SEK 57 million and amounted to SEK 16 million (-41). In addition to less non-repeating activities, it is driven by efficiency improvements and cost control. Improving our financial results was a cornerstone of successfully refinancing our corporate bond in the quarter, and we gained strong interest from investors with close to 100 percent oversubscription. Our R&D projects continue to show progress, although OX124 is likely to require a longer review than the original PDUFA date in July based on recent request for additional documentation. Our ambition remains to launch the product in late 2024 or early 2025. For the full CEO Comments read the PDF Contact persons quarterly report Presentation On May. 8, at 1 pm CET analysts, investors and media are invited to attend a presentation, incl. a Q&A. To attend via teleconference where you can ask questions verbally: To attend via webcast: https://ir.financialhearings.com/orexo-q1-report-2024 Prior to the call, presentation material will be available on the website under Investors/ Reports/Audiocasts. This information is information that Orexo AB (publ.) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication through the agency of the contact persons set out above at 8 am CET on May 8, 2024. This information was brought to you by Cision http://news.cision.com https://news.cision.com/orexo/r/orexo-q1-2024-interim-report,c3975281 The following files are available for download:
View original content:https://www.prnewswire.com/news-releases/orexo-q1-2024-interim-report-302139330.html SOURCE Orexo | |||||||||||||||||||||||||||||||||||||||||||||||||
Company Codes: Stockholm:ORX, OTC-PINK:ORXOY, ISIN:SE0000736415, RICS:ORX.ST |